David Sugarbaker, Director of the International Mesothelioma Program, discusses the use of extrapleural pneumonectomy in the treatment of mesothelioma.
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Prognostic analysis of salvage esophagectomy after definitive chemoradiotherapy for esophageal squamous cell carcinoma: The importance of lymphadenectomy
May 21, 2014
Pts undergoing salvage esophagectomy after definitive chemoradiotherapy were evaluated for perdictors of survival. 5-year survival was 30%, which was related to tumor recurrence rather than residual tumor, complete resection, N status, M status, and dissection of more than 15 nodes. Additional neck dissection was not found to provide additional ben
Shifting Patterns in the Interpretation of Phase III Clinical Trial Outcomes in Advanced Non–Small-Cell Lung Cancer: The Bar Is Dropping
May 21, 2014
This study evaluated over 200 RTCs of systemic therapy for NSCLC. There has been a steady increase in the number of trials reporting outcomes for progression-free survival. Over 50% of trials now report a positive outcome without meeting the primary endpoint of the trial. Although the sample size of the trials is increasing, the magnitude of repor
St. Jude Medical Announces First Implants in US Study of the Portico Transcatheter Aortic Heart Valve System
May 21, 2014
The PORTICO trial has opened to evaluate the Portico Transcatheter Aortic Valve System. This prospective multicenter trial involving up to 40 sites will randomize pts to Portico vs another TAVR valve in the US.
May 15, 2014
Betty Tong, Co-Director of the Lung Cancer Screening Program at Duke University Medical Center, discusses the process of establishing a lung cancer screening program.
May 9, 2014
Using the Nationwide Inpatient Sample, the authors evaluated outcomes and costs of VATS (37,595) vs robotic (2,498) lobectomy 2008-2011. Robotic lobectomy was associated with higher rates of complications, particularly cardiovascular and iatrogenic bleeding, and higher costs ($22,582 vs $17,874).
May 6, 2014
67 patients without a previous history of lung cancer underwent FNA of a GGO with results suspicious for, but not diagnostic of, adenocarcinoma. 47 pts who elected to undergo resection were compared to 16 who opted for observation. 6/16 observed pts developed interval growth or increase in the solid component of the GGO and 5 underwent resection or
Predictive Value of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification of Lung Adenocarcinoma in Tumor Recurrence and Patient Survival
May 6, 2014
Clinical outcomes of patients with lung adenocarcinoma were analyzed with respect to the histologic subtype of adenocarcinoma. Histologic pattern was associated with sex, T status, N status, and stage. Recurrence was higher in patients with micropapillary and solid tumors.
Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data
May 3, 2014
This systematic review and meta-analysis of individual patient data from 15 RCTs (2385 pts) assessed the utility of preoperative chemotherapy in patients with primarily stages Ib-IIIa NSCLC. Chemotherapy resulted in a 13% reduction in death (HR 0.87, p=0.007), and a 5% survival improvement at 5 years.
May 1, 2014
A panel for the Centers for Medicare and Medicaid determined that annual low-dose CT screening for lung cancer carries too high a risk related to the potential benefits. They expressed concern about high false-positive rates, quality assurance, and gaps in evidence as to how the CT results would be used. Despite the fact that many professional grou